Results 11 to 20 of about 4,732,777 (361)

Expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition) [PDF]

Zhongguo aizheng zazhi, 2022
Neoadjuvant therapy has become one of the standard treatments in early breast cancer. In 2019, China breast cancer neoadjuvant therapy expert group discussed and expounded the purpose, indication, evaluation criteria, surgical operation principles and ...
Expert group of expert consensus on neoadjuvant treatment of breast cancer in China ( edition)
doaj   +1 more source

Neoadjuvant therapy in patients with locally advanced colon cancer [PDF]

Waike lilun yu shijian, 2022
It is still unclear about neoadjuvant therapy in patients with locally advanced colon cancer (LACC). This review summarized neoadjuvant chemotherapy, neoadjuvant chemotherapy combined with targeted therapy and combined radio-chemotherapy for the patients
XU Zifeng, ZONG Yaping, LU Aiguo
doaj   +1 more source

Neoadjuvant Therapy for Locally Advanced Esophageal Cancers

Frontiers in Oncology, 2022
Esophageal carcinoma is one of the most aggressive malignant diseases. At present, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy are regarded as the standard modalities for the treatments of locally advanced esophageal cancers based on ...
Runkai Huang, Zhenbin Qiu, Chunwen Zheng, Ruijie Zeng, Wanxian Chen, Simeng Wang, Enmin Li, Yiwei Xu, Yiwei Xu   +8 more
doaj   +1 more source

Neoadjuvant therapy for gallbladder cancer: current status and challenge [PDF]

Waike lilun yu shijian, 2023
Gallbladder cancer is one of highly malignant digestive system tumors with insidious symptoms, rapid progression, and poor prognosis. Although radical resective surgery is the only possible curative way for gallbladder cancer, most patients have lost the
XING Ying, CHENG Shi
doaj   +1 more source

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)

Frontiers in Oncology, 2023
BackgroundThe emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in the treatment landscape of non-small cell lung cancer (NSCLC).
Qin Wang, Chen Qi, Jing Luo, Nan Xu, Mao-tian Xu, Yong Qiang, Chi Zhang, Yi Shen   +7 more
doaj   +1 more source

Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report

Heliyon, 2023
Purpose: Platinum-based regimens are regarded as the preferred alternative for neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC) patients. However, some patients cannot tolerate platinum-based regimens. We report an MIBC case with severe
Haijun Huang, Yucong Zhang, Zhi Chen, Xing Zeng, Zhiquan Hu, Chunguang Yang   +5 more
doaj   +1 more source

Impact on CD4+ CD25High-CD127low regulatory T (Treg) cells of neoadjuvant therapy for rectal cancer patients

Indian Journal of Pathology and Microbiology, 2023
Background: The efficacy of neoadjuvant therapy for rectal cancer has not been assessed. Objective: To evaluate proportional changes in peripheral blood immune cells in rectal cancer patients after neoadjuvant therapy and assess the relationship between ...
Liu Maoxi, Liu Haiyi
doaj   +1 more source

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

Frontiers in Pharmacology, 2023
Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation ...
Yongbao Wei, Yongbao Wei, Ruochen Zhang, Ruochen Zhang, Dewen Zhong, Zhensheng Chen, Gen Chen, Minggen Yang, Le Lin, Le Lin, Tao Li, Tao Li, Liefu Ye, Liefu Ye, Lili Chen, Lili Chen, Qingguo Zhu, Qingguo Zhu   +17 more
doaj   +1 more source

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression

Frontiers in Oncology, 2022
IntroductionNeoadjuvant trastuzumab plus chemotherapy may affect programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer.
Mao Shang, Mao Shang, Yajing Chi, Jianbo Zhang, Jin Chang, Hui Yang, Sha Yin, Qiaorui Tan, Xiaochu Man, Huihui Li   +9 more
doaj   +1 more source

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation

Frontiers in Oncology, 2022
Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated.
Chaoyuan Liu, Min Lu, Yang Yang, Xiang Wang, Fang Ma, Xianling Liu   +5 more
doaj   +1 more source